BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN) today announced that it has completed a single ascending dose, first-in-human study with NGD-4715, the Company’s leading drug candidate for the treatment of obesity. NGD-4715 works as a small molecule antagonist at the melanin concentrating hormone receptor-1 (MCHR1). The compound was safe and well tolerated at all doses studied in this clinical trial.
